C0460000
Carbidopa
European Pharmacopoeia (EP) Reference Standard
동의어(들):
(S)-3-(3,4-Dihydroxyphenyl)-2-hydrazino-2-methylpropionic acid monohydrate
로그인조직 및 계약 가격 보기
모든 사진(1)
About This Item
실험식(Hill 표기법):
C10H14N2O4 · H2O
CAS Number:
Molecular Weight:
244.24
MDL number:
UNSPSC 코드:
41116107
PubChem Substance ID:
NACRES:
NA.24
추천 제품
Grade
pharmaceutical primary standard
API family
carbidopa
제조업체/상표
EDQM
응용 분야
pharmaceutical (small molecule)
형식
neat
SMILES string
O.C[C@@](Cc1ccc(O)c(O)c1)(NN)C(O)=O
InChI
1S/C10H14N2O4.H2O/c1-10(12-11,9(15)16)5-6-2-3-7(13)8(14)4-6;/h2-4,12-14H,5,11H2,1H3,(H,15,16);1H2/t10-;/m0./s1
InChI key
QTAOMKOIBXZKND-PPHPATTJSA-N
유전자 정보
human ... DDC(1644)
유사한 제품을 찾으십니까? 방문 제품 비교 안내
일반 설명
Carbidopa is a dopaminergic drug, which is known to inhibit the conversion of dopa to dopamine. It is used in combination with levodopa for the effective treatment of restless legs syndrome and periodic leg movements in sleep.
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
애플리케이션
Carbidopa EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
포장
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
기타 정보
Sales restrictions may apply.
관련 제품
제품 번호
설명
가격
신호어
Warning
유해 및 위험 성명서
Hazard Classifications
Acute Tox. 4 Oral - Eye Irrit. 2
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
가장 최신 버전 중 하나를 선택하세요:
이미 열람한 고객
The effect of carbidopa administration on urinary sodium excretion in man. Is dopamine an intrarenal natriuretic hormone?
Ball.G.S and Lee.R.M
British Journal of Clinical Pharmacology, 4(2), 115- 119 (1977)
Augmentation of the restless legs syndrome with carbidopa/levodopa
Allen.PR and Earley.JC
Sleep, 19(3), 205-213 (1996)
Àlex Pericas et al.
Organic letters, 15(7), 1448-1451 (2013-03-13)
A stereoselective synthesis of L-carbidopa in seven steps and 50% overall yield from commercial compounds is described. The key step involves a highly enantioselective α-amination reaction of an acyclic β-ketoester with di-tert-butyl azodicarboxylate induced by europium and (R,R)-diphenyl-pybox.
Robert A Hauser
Expert review of neurotherapeutics, 12(2), 133-140 (2012-02-01)
Levodopa (LD) remains the most effective medication to treat Parkinson's disease (PD). However, most patients develop motor fluctuations and dyskinesias with long-term LD use. It is thought that these response complications are due, at least in part, to LD's short
J T Hutton et al.
Neurology, 42(1 Suppl 1), 51-56 (1992-01-01)
Parkinson's disease patients treated chronically with levodopa often develop fluctuations in motor response. Motor fluctuations can be attributed in part to oscillating plasma levodopa concentrations. A controlled-release formulation containing 200 mg of levodopa and 50 mg of carbidopa provides superior
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.